Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective

Systemic treatment of renal cancer (RCC) has undergone remarkable changes over the past 20 years with the introduction of immunotherapeutic agents targeting programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) axis, as a single-agent or combined with anti-CTLA-4 monoclonal antibodies (MoAb...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Mol Sci
Egile Nagusiak: Lavacchi, Daniele, Pellegrini, Elisa, Palmieri, Valeria Emma, Doni, Laura, Mela, Marinella Micol, Di Maida, Fabrizio, Amedei, Amedeo, Pillozzi, Serena, Carini, Marco, Antonuzzo, Lorenzo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2020
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7369721/
https://ncbi.nlm.nih.gov/pubmed/32630154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21134691
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak